Endocannabinoid membrane transporter (EMT) (EMT)

The endocannabinoid membrane transporter (EMT), also known as the anandamide uptake system, is a functional entity responsible for the cellular internalization of endocannabinoids, primarily N-arachidonoylethanolamine (anandamide or AEA) (PubMed, 2012). This process is a critical step in the termination of endocannabinoid signaling, as it facilitates the movement of AEA from the extracellular space to intracellular compartments where it is degraded by enzymes like fatty acid amide hydrolase (FAAH) (NIH, 2004). While a single, definitive transmembrane protein has not been identified, the system is thought to involve facilitated diffusion and intracellular carrier proteins such as fatty acid-binding proteins (FABP5 and FABP7) and the FAAH-like anandamide transporter (FLAT) (Wikipedia, 2024; NIH, 2013). Pharmacological inhibition of this uptake system, using compounds like AM404 or SB-FI-26, leads to elevated levels of endogenous anandamide and prolonged activation of cannabinoid receptors (CB1 and CB2) (PubMed, 2012). This mechanism offers a therapeutic pathway for treating conditions such as chronic pain, inflammation, and anxiety by enhancing the body's natural endocannabinoid tone without the side effects of direct agonists (NIH, 2012). Consequently, the EMT is a significant target in neuropharmacology, despite the ongoing debate regarding its precise molecular composition (Frontiers, 2014). Research continues to explore its role in neuroprotection and metabolic regulation, making it a versatile target for diverse clinical applications (NIH, 2023). The development of selective inhibitors for specific components of the system, such as FABPs, represents a novel strategy for drug discovery (NIH, 2012).

Other names

Anandamide membrane transporterAnandamide transporterEndocannabinoid transporterAnandamide uptake systemAMTEMTECTFAAH-like anandamide transporter (FLAT)Fatty acid-binding protein 5 (FABP5)Fatty acid-binding protein 7 (FABP7)

Inhibition of anandamide uptake and intracellular transport, resulting in increased extracellular endocannabinoid levels and enhanced activation of cannabinoid and vanilloid receptors (PubMed, 2012).